NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Roche Holding AG (MX: ROGN)

 
ROGN Technical Analysis
5
As on 17th Sep 2025 ROGN STOCK Price closed @ 6042.01 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 4760.12 & Strong Buy for SHORT-TERM with Stoploss of 5201.98 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

ROGNSTOCK Price

Open 6042.01 Change Price %
High 6042.01 1 Day -186.58 -3.00
Low 6042.01 1 Week 157.61 2.68
Close 6042.01 1 Month -1070.55 -15.05
Volume 82 1 Year 774.12 14.70
52 Week High 7169.32 | 52 Week Low 4000.08
 
MX Mexico Most Active Stocks
AMXL 19.28 -0.36%
WALMEX 56.89 0.19%
CEMEXCPO 17.29 -0.58%
FR 617.33 -35.98%
GFNORTEO 186.57 0.91%
GMEXICOB 135.09 -1.66%
ALFAA 14.59 -1.42%
FUNO11 28.85 -1.50%
LABB 19.98 -1.62%
FEMSAUBD 170.58 -1.77%
 
MX Mexico Top Gainers Stocks
ALEATIC 49.86 141.69%
MKSN 54.86 92.49%
GNW 160.21 57.38%
GNW 160.21 57.38%
HBCN 1200.00 28.34%
FIBRAUP18 39.19 20.58%
BIDUN 2499.23 18.45%
BAPN 4735.00 15.08%
UTSI 50.85 13.00%
UTSI 50.85 13.00%
 
MX Mexico Top Losers Stocks
FR 617.33 -35.98%
FR 617.33 -35.98%
FR 617.33 -35.98%
FR 617.33 -35.98%
AGLN 502.53 -25.55%
IP 872.75 -23.50%
IP 872.75 -23.50%
IP 872.75 -23.50%
IP 872.75 -23.50%
IP 872.75 -23.50%
 
 
ROGN
Daily Charts
ROGN
Intraday Charts
Whats New @
Bazaartrend
ROGN
Free Analysis
 
ROGN Important Levels Intraday
RESISTANCE6042.01
RESISTANCE6042.01
RESISTANCE6042.01
RESISTANCE6042.01
RESISTANCE6042.01
RESISTANCE6042.01
RESISTANCE6042.01
RESISTANCE6042.01
 
ROGN Forecast September 2025
4th UP Forecast6423.79
3rd UP Forecast6301.35
2nd UP Forecast6225.67
1st UP Forecast6149.99
1st DOWN Forecast5934.03
2nd DOWN Forecast5858.35
3rd DOWN Forecast5782.67
4th DOWN Forecast5660.23
 
ROGN Weekly Forecast
4th UP Forecast6135.03
3rd UP Forecast6105.20
2nd UP Forecast6086.76
1st UP Forecast6068.32
1st DOWN Forecast6015.70
2nd DOWN Forecast5997.26
3rd DOWN Forecast5978.82
4th DOWN Forecast5948.99
 
ROGN Forecast2025
4th UP Forecast12149.1
3rd UP Forecast10190.5
2nd UP Forecast8979.9
1st UP Forecast7769.25
1st DOWN Forecast4314.77
2nd DOWN Forecast3104.12
3rd DOWN Forecast1893.47
4th DOWN Forecast-65.12
 
 
ROGN Other Details
Segment EQ
Market Capital 6755751821312.00
Sector Healthcare
Industry Drug Manufacturers-General
Offical website >
 
ROGN Address
ROGN
 
ROGN Latest News
 
Your Comments and Response on Roche Holding AG
 
ROGN Business Profile
Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women's health. In addition, it supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. The company has collaboration with Gilead Sciences, Inc. for COVID-19; a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza, as well as SemaThera Inc. to develop biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases; and has collaboration with Affimed N.V to study AFM24 in combination with PD-L1 checkpoint inhibitor in EGFR expressing solid tumors, as well as with Surface Oncology, Inc. to evaluate SRF388. It also has a clinical collaboration with Carrick Therapeutics, Ltd. to evaluate a novel combination of Carrick's samuraciclib and its giredestrant in CDK4/6i resistant HR+, HER2- metastatic breast cancer. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland. Address: Konzern Hauptsitz, Basel, Switzerland, 4070
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service